Alpha 2.0
Login Register
» Authors » Maurice P H M Jansen

Maurice P H M Jansen

Explore the profile of Maurice P H M Jansen including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 48
Citations 1009
Followers 0
Related Specialties
Oncology
Molecular Biology
Biochemistry
Top 10 Co-Authors
John W M Martens
Els M J J Berns
Stefan Sleijfer
John A Foekens
Anieta M Sieuwerts
Maxime P Look
Silvia R Vitale
Kirsten Ruigrok-Ritstier
Jean C A Helmijr
Iris L van Staveren
Published In
Mol Oncol
Breast Cancer Res Treat
BMC Cancer
J Clin Oncol
Transl Oncol
Affiliations
Soon will be listed here.
Recent Articles
11.
Dutch National Round Robin Trial on Plasma-Derived Circulating Cell-Free DNA Extraction Methods Routinely Used in Clinical Pathology for Molecular Tumor Profiling
van der Leest P, Ketelaar E, van Noesel C, van den Broek D, van Boerdonk R, Deiman B, et al.
Clin Chem . 2022 May; 68(7):963-972. PMID: 35616097
Background: Efficient recovery of circulating tumor DNA (ctDNA) depends on the quantity and quality of circulating cell-free DNA (ccfDNA). Here, we evaluated whether various ccfDNA extraction methods routinely applied in...
12.
The COMPLETE trial: HolistiC early respOnse assessMent for oroPharyngeaL cancEr paTiEnts; Protocol for an observational study
Verduijn G, Capala M, Sijtsema N, Lauwers I, Hernandez Tamames J, Heemsbergen W, et al.
BMJ Open . 2022 May; 12(5):e059345. PMID: 35584883
Introduction: The locoregional failure (LRF) rate in human papilloma virus (HPV)-negative oropharyngeal squamous cell carcinoma (OPSCC) remains disappointingly high and toxicity is substantial. Response prediction prior to or early during...
13.
The prognostic and predictive value of ESR1 fusion gene transcripts in primary breast cancer
Vitale S, Ruigrok-Ritstier K, Timmermans A, Foekens R, Trapman-Jansen A, Beaufort C, et al.
BMC Cancer . 2022 Feb; 22(1):165. PMID: 35151276
Background: In breast cancer (BC), recurrent fusion genes of estrogen receptor alpha (ESR1) and AKAP12, ARMT1 and CCDC170 have been reported. In these gene fusions the ligand binding domain of...
14.
Plasma Cell-Free DNA Testing of Patients With EGFR Mutant Non-Small-Cell Lung Cancer: Droplet Digital PCR Versus Next-Generation Sequencing Compared With Tissue-Based Results
Steendam C, Atmodimedjo P, de Jonge E, Paats M, van der Leest C, Oomen-de Hoop E, et al.
JCO Precis Oncol . 2022 Feb; 3:1-9. PMID: 35100738
Purpose: To compare the results of plasma cell-free DNA (cfDNA) droplet digital PCR (ddPCR) and next-generation sequencing (NGS) on detection of epidermal growth factor receptor () primary activating mutations and...
15.
Liquid biopsy in esophageal cancer: a case report of false-positive circulating tumor DNA detection due to clonal hematopoiesis
Spoor J, Eyck B, Atmodimedjo P, Jansen M, Helmijr J, Martens J, et al.
Ann Transl Med . 2021 Sep; 9(15):1264. PMID: 34532401
Circulating tumor DNA (ctDNA) analysis is a promising non-invasive technique for active surveillance after chemoradiotherapy for locally advanced resectable esophageal carcinoma. In other malignancies false-positive results in ctDNA analysis have...
16.
Optimizing Nanopore sequencing-based detection of structural variants enables individualized circulating tumor DNA-based disease monitoring in cancer patients
Espejo Valle-Inclan J, Stangl C, de Jong A, van Dessel L, van Roosmalen M, Helmijr J, et al.
Genome Med . 2021 May; 13(1):86. PMID: 34006333
Here, we describe a novel approach for rapid discovery of a set of tumor-specific genomic structural variants (SVs), based on a combination of low coverage cancer genome sequencing using Oxford...
17.
Detection of oncogenic mutations in paired circulating tumor DNA and circulating tumor cells in patients with hepatocellular carcinoma
Ge Z, Helmijr J, Jansen M, Boor P, Noordam L, Peppelenbosch M, et al.
Transl Oncol . 2021 Apr; 14(7):101073. PMID: 33915518
Background And Aims: Circulating tumor cells (CTCs) or circulating tumor DNA (ctDNA) may be used for diagnostic or prognostic purposes in patients with hepatocellular carcinoma (HCC). We aim to determine...
18.
Detection of tumor-derived extracellular vesicles in plasma from patients with solid cancer
Vitale S, Helmijr J, Gerritsen M, Coban H, van Dessel L, Beije N, et al.
BMC Cancer . 2021 Mar; 21(1):315. PMID: 33761899
Background: Extracellular vesicles (EVs) are actively secreted by cells into body fluids and contain nucleic acids of the cells they originate from. The goal of this study was to detect...
19.
Optimization of Pancreatic Juice Collection: A First Step Toward Biomarker Discovery and Early Detection of Pancreatic Cancer
Levink I, Nesteruk K, Visser D, Sieuwerts A, Fernandes C, Jansen M, et al.
Am J Gastroenterol . 2020 Oct; 115(12):2103-2108. PMID: 33105193
Introduction: Imaging-based surveillance programs fail to detect pancreatic ductal adenocarcinoma at a curable stage, creating an urgent need for diagnostic biomarkers. Methods: Secretin-stimulated pancreatic juice (PJ) was collected from the...
20.
Comparison of variant allele frequency and number of mutant molecules as units of measurement for circulating tumor DNA
Bos M, Nasserinejad K, Jansen M, Angus L, Atmodimedjo P, de Jonge E, et al.
Mol Oncol . 2020 Oct; 15(1):57-66. PMID: 33070443
Quantification of tumor-specific variants (TSVs) in cell-free DNA is rapidly evolving as a prognostic and predictive tool in patients with cancer. Currently, both variant allele frequency (VAF) and number of...